Physician profile
Thomas Renfro
NPI 1497726376
$2,422.10
in general payments reported to CMS, 2019-2025
27 companies · $59.34 in 2025
The $59.34 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $650 · 2021: $558 · 2022: $327 · 2023: $373 · 2024: $169 · 2025: $59.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $601.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $601.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $429.83 | 2020-2024 | |
| Novo Nordisk INC | $339.60 | 2019-2024 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $270.40 | 2019-2022 | |
| Lilly USA, LLC | $204.91 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Astrazeneca Pharmaceuticals LP | $193.33 | 2019-2025 | Breztri, Farxiga |
| Novartis Pharmaceuticals Corporation | $143.73 | 2019-2023 | |
| Amgen INC. | $132.01 | 2019-2024 | Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.65 | 2021-2023 | |
| Allergan, INC. | $55.94 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $50.46 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.86 | 2023-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $45.75 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $44.68 | 2020-2022 | |
| Glaxosmithkline, LLC. | $42.96 | 2020-2024 | Trelegy Ellipta |
| Pfizer INC. | $40.55 | 2020-2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $36.13 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $33.15 | 2021 | |
| Xeris Pharmaceuticals, INC. | $32.05 | 2023 | Gvoke Hypopen |
| Sumitomo Pharma America, INC. | $24.12 | 2023 | Gemtesa |
| Exact Sciences Corporation | $23.42 | 2024 | Cologuard Collection Kit |
| Astellas Pharma US INC | $23.30 | 2023 | Veozah |
| Scynexis, INC. | $19.07 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.34 | 2022 | |
| Abbott Laboratories | $15.28 | 2024 | Freestyle Libre 3 |
| Neurocrine Biosciences, INC. | $15.13 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.97 | 2022 | |
| Eisai INC. | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Renfro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.